Coherus Biosciences Inc (NASDAQ:CHRS) CFO Jean-Frederic Viret Sells 740 Shares

Coherus Biosciences Inc (NASDAQ:CHRS) CFO Jean-Frederic Viret sold 740 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $21.78, for a total transaction of $16,117.20. Following the completion of the sale, the chief financial officer now owns 7,773 shares of the company’s stock, valued at approximately $169,295.94. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jean-Frederic Viret also recently made the following trade(s):

  • On Wednesday, September 18th, Jean-Frederic Viret sold 3,159 shares of Coherus Biosciences stock. The shares were sold at an average price of $20.44, for a total transaction of $64,569.96.
  • On Wednesday, August 21st, Jean-Frederic Viret sold 6,318 shares of Coherus Biosciences stock. The shares were sold at an average price of $21.71, for a total transaction of $137,163.78.
  • On Monday, August 19th, Jean-Frederic Viret sold 3,000 shares of Coherus Biosciences stock. The shares were sold at an average price of $19.04, for a total transaction of $57,120.00.

Shares of NASDAQ CHRS traded up $0.43 during midday trading on Wednesday, reaching $22.53. 2,243,125 shares of the stock were exchanged, compared to its average volume of 933,986. The company has a 50 day simple moving average of $20.59 and a 200 day simple moving average of $18.16. The stock has a market capitalization of $1.56 billion, a P/E ratio of -7.00 and a beta of 2.95. Coherus Biosciences Inc has a twelve month low of $8.32 and a twelve month high of $23.91.



Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.40. The firm had revenue of $83.43 million for the quarter, compared to analyst estimates of $81.05 million. On average, research analysts predict that Coherus Biosciences Inc will post 0.89 earnings per share for the current year.

A number of analysts have commented on the stock. Robert W. Baird set a $28.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Wednesday, June 19th. ValuEngine downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Mizuho initiated coverage on shares of Coherus Biosciences in a report on Tuesday, August 13th. They set a “buy” rating and a $43.00 price target for the company. BidaskClub downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Friday, September 6th. Finally, Barclays set a $31.00 price target on shares of Coherus Biosciences and gave the stock a “buy” rating in a report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.38.

Several large investors have recently bought and sold shares of the stock. HighTower Advisors LLC boosted its position in shares of Coherus Biosciences by 6.4% during the 2nd quarter. HighTower Advisors LLC now owns 12,184 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 734 shares during the period. United Services Automobile Association boosted its position in shares of Coherus Biosciences by 0.9% during the 2nd quarter. United Services Automobile Association now owns 217,216 shares of the biotechnology company’s stock worth $4,800,000 after purchasing an additional 1,950 shares during the period. Brown Advisory Inc. boosted its position in shares of Coherus Biosciences by 0.5% during the 2nd quarter. Brown Advisory Inc. now owns 656,455 shares of the biotechnology company’s stock worth $14,508,000 after purchasing an additional 3,061 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Coherus Biosciences by 15.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 25,485 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 3,390 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Coherus Biosciences during the 2nd quarter worth approximately $75,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Story: Street Name

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.